Biomarker Profiles in Serum and CSF for Early Diagnosis of Selected Neurodegenerative Diseases

• DOI: 10.54393/pjhs.v5i09.2153
• Publication Date: 2024-10-16T08:12:22Z
• Authors: Muhammad Anique; Masooma Talib; Amna Ihsan; Iqra Anwar; Ambreen Zeeshan; Naveed Ahsan

Biomarker research and justification for neurodegenerative illnesses have seen enormous efforts over the last ten years. Bio-fluid-based biomarkers been believed to provide a better easier approach detecting diagnosing nervous system pathologies. Objectives: To evaluate diagnostic potential of certain in serum cerebrospinal fluid diagnose Alzheimer’s disease, Parkinson’s Huntington’s disease at an initial stage. Methods: 280 participants were taken distributed into four groups, comprising, 70 patients with early-stage age-matched healthy controls. Blood samples drawn medical history was from patients. Serum levels amyloid-beta (Aβ42), total tau (t-tau), phosphorylated (p-tau), alpha-synuclein, huntingtin protein, neuro-filament light chain evaluated using enzyme-linked immunosorbent assays. Results: showed reduced Aβ42 (80.4 ± 15.6 pg/mL) elevated t-tau (140.5 18.2 pg/mL). had raised alpha-synuclein (12.5 2.3 ng/mL) chain. significant increases protein (8.2 2.0 ng/mL). These profiles indicate efficacy early diagnosis. Conclusions: It concluded that effectively detect while can be diagnosed Similarly, are sensitive enough its stages.